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TSG-5' resistanceThe Pro-Ser-Ala-Pro (PSAP)motif in the p2 domain of feline immunodeﬁciency virus (FIV) Gag is required for ef-
ﬁcient virus release, virus replication, and Gag binding to the ubiquitin-E2-variant (UEV) domain of Tsg101. As a
result of this direct interaction, expression of an N-terminal fragment of Tsg101 containing the UEV domain
(referred to as TSG-5′) inhibits FIV release. In these respects, the FIV p2Gag PSAP motif is analogous to the PTAP
motif of HIV-1 p6Gag. To evaluate the feasibility of a late domain-targeted inhibition of virus replication, we cre-
ated an enriched Crandell-Rees feline kidney (CRFK) cell line (T5′hi) that stably expresses high levels of TSG-5′.
Herewe show thatmutations in either the V3 loopor the second heptad repeat (HR2) domain of the FIV envelope
glycoprotein (Env) rescue FIV replication in T5′hi cells without increasing FIV release efﬁciency. TSG-5′-resistance
mutations in Env enhance virion infectivity and the cell–cell spread of FIVwhen diffusion is limited using a semi-
solid growthmedium. Theseﬁndings show thatmutations in functional domains of Env confer TSG-5′-resistance,
which we propose enhances speciﬁc infectivity and the cell–cell transmission of virus to counteract inefﬁcient
virus release. This article is part of a Special Issue entitled: Viral Membrane Proteins—Channels for Cellular
Networking.
Published by Elsevier B.V.1. Introduction
The efﬁcient release of retroviruses and many other enveloped
viruses relies on a direct interaction with endosomal sorting complexes
required for transport (ESCRTs) or ESCRT-associated proteins [1].
Speciﬁcally, interactions with the ESCRT-I component TSG101, Nedd4
and Nedd4-like HECT ubiquitin ligases associated with ESCRT, or the
ESCRT-I/III-interacting protein Alix appear to be the most highly con-
served for this function [2–9]. The four known ESCRT complexes
(ESCRT-0,I,II,III) normally function in the turnover of ubiquitinated
membrane-bound protein cargo through a series of interactions with
each ESCRT that ultimately targets the cargo for degradation by vesicu-
lar budding into late endosomal compartments called multivesicular
bodies (MVB) and subsequent delivery to the lysosome [10–13]. ESCRTs
also play a role in othermembrane scission events that occur during cy-
tokinesis and the budding of enveloped viruses from the plasma mem-
brane [14–18]. Interactionswith ESCRT occur through binding ubiquitinmbrane Proteins—Channels for
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.and short peptide motifs that are unique for each ESCRT [19]. Viruses
tap into this system by encoding one or sometimes multiple ESCRT-
recognizing motifs in their major structural protein, which is often
ubiquitinated [20–28]. Invariably, these viral motifs consist of one or
two critical proline residues (PT/SAP, PPxY, YPXnL, FPIV). Due to the
profound defects in events that occur late in the virus replication cycle
if these motifs are altered, speciﬁcally virus release, these motifs have
been termed “late” domains [29]. The best characterized mechanism
for late domain function is that of HIV-1 Gag p6, which contains a
PTAP sequence that directly interacts with the ubiquitin E2-like variant
(UEV) domain of TSG101 [30]. This mimics the function of a PSAP se-
quence in the heptocyte growth factor-regulated tyrosine kinase sub-
strate (HRS), which is an ESCRT-0 component associated with early
endosomes that also binds the UEV domain of TSG101 [22,31]. The PT/
SAP late domain has been widely studied because it is so highly con-
served in the Gag protein of retroviruses, including most primate lenti-
viruses (sometimes in tandem), and most other lentiviruses [21,32]. A
functional PTAP late domain is also found in the matrix protein of at
least two highly pathogenic viruses – the ﬁlovirus Ebola VP40 protein
and the arenavirus Lassa Z protein [33,34]. Often each virus only con-
tains one late domain; however there are several examples of viruses
that contain two or even three, which sometimes overlap. In primate
lentiviruses, the PTAP motif often plays a more dominant role over
Alix-binding motifs. For example, HIV-1 Gag p6 contains a secondary
late domain consisting of a YPXnL sequence that binds the V domain
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under speciﬁc conditions and cellular environments [35,36]. Similar
Alix-binding late domains have also recently been identiﬁed in SIV
[37,38].
FIV causes AIDS in domestic cats and is a model for HIV-1-
associated pathogenesis, cellular biology, and vaccine development
[32,39–44]. Despite having very little sequence homology with
HIV-1, we and others have shown that the molecular mechanisms
and organization of functional domains for FIV virion assembly and
release, proteolytic maturation of Gag and Env, Env-mediated recep-
tor/co-receptor binding andmembrane fusion, reverse transcription,
integration, latency, Rev-dependent export of genomic RNA, and
targeting of antiviral restriction factors are all highly conserved
with those of HIV-1 and other primate lentiviruses [32,44–62]. For
example, the PSAP motif in the C-terminal p2 domain of FIV Gag
functions equivalently to the PTAP motif in HIV-1 Gag p6 in its role
in FIV release and direct interaction with TSG101 [5,46]. Unlike
HIV-1, however, FIV does not contain a secondary YPXnL-type late
domain and is insensitive to agents that would disrupt interactions
with the Alix-V domain [46]. We previously demonstrated that ex-
pression of the N-terminal half of TSG101 (TSG-5′) containing the
UEV domain functions in a dominant manner to inhibit HIV-1 and
FIV release [15,46,63]. We also developed feline cell lines that consti-
tutively express TSG-5′ and described their restriction of FIV replica-
tion. In this report, we have now identiﬁed two mutations in the FIV
Env glycoprotein that rescue FIV replication. One of these involves
mutation of the V3 loop in the surface (SU) subunit of FIV Env,
which is analogous to the V3 loop of HIV-1 SU in terms of its role in
coreceptor binding, heparan sulfate proteoglycan (HSPG) binding,
and as an epitope for neutralizing antibodies [64–71]. The other mu-
tation is in the second heptad repeat (HR2) of the transmembrane
subunit (TM). This region is analogous to the HR2 of HIV-1 TM,
which is the site of the fusion inhibitor enfuvirtide (T20) peptide se-
quence, where mutations that accompany T20 resistance can also
develop, and has received interest as a site for neutralizing antibody
epitopes [72–74]. We propose that these mutations provide resis-
tance to the TSG-5′-mediated inhibition of virus release not by rescu-
ing virus release but rather by enhancing virion infectivity and cell-
to-cell transmission.
2. Materials and methods
2.1. Plasmids and site-directed mutagenesis
pFIV-34TF10 is an infectiousmolecular clone of the Petaluma isolate
[75] obtained from J. Elder (Scripps Research Institute, La Jolla, CA)
through the NIH AIDS Research and Reference Reagent Program. pFIV-
O2R is a derivative of pFIV-34TF10with a repaired ORF2 gene, which in-
creases infectivity in feline lymphocytes and does not inhibit replication
in CRFK cells [76]. pFP93 [a gift fromE. Poeschla (Mayo Clinic, Rochester,
MN)] is an FIV gag-pol expression vector deleted for Env, Vif, and LTRs
that uses a CMV promoter to express non-infectious FIV–Petaluma
virus-like particles (VLPs) in human cells [77]. pHCMV-G, which ex-
presses the G glycoprotein of vesicular stomatitis virus (VSV), was a
gift from J. Burns (University of California, San Diego). pFIV–Env is a de-
rivative of pFIV-O2R that expresses the full-length FIV–Petaluma Env
and Rev in feline cells using its native promoter, constructed by deletion
of an XhoI-KpnI fragment containing the RNA packaging signal, gag, pol,
and vif, and an insertion of a compatible SalI-KpnI fragment of pFP93,
which encodes the 5′ end of both env and rev. pFIV–Env or pFIV–O2R
clones containing TSG-5′ resistance mutations were made by site-
directed mutagenesis using the QuikChange II XL mutagenesis kit
(Stratagene) and synthetic complementary oligonucleotides (Sigma
Genosys). To detect any potential ampliﬁcation of DNA polymerase er-
rors during mutagenesis, the entire coding region of all mutant clones
was fully sequenced prior to use.2.2. Cell culture
Crandell-Rees feline kidney cells CRFK [78] (a gift from S. Le Grice, HIV
Drug Resistance Program, National Cancer Institute, Frederick, MD),
293 T, and HeLa cells were maintained in either Eagle MEM (E-MEM;
ATCC) for CRFK or D-MEM (Gibco) for 293 T and HeLa, supplemented
with 10% fetal bovine serum (FBS; HyClone), penicillin, streptomycin,
and glutamine (Gibco).
2.3. Virus release assays
FIV Gag was detected by radioimmunoprecipitation assay (RIPA) as
previously described [46,79–81]. Brieﬂy, CRFK cells were transfected
with vectors expressing FIV proteins or TSG-5′ using Lipofectamine
LTX, following the manufacturer's suggested protocol. Cells were meta-
bolically labeled at 37 °C with [35S] Met/Cys (Express Protein-Labeling
Mix; PerkinElmer) for 4 h. Released virions or VLPs were collected by
ﬁltration of cultured cell supernatant and ultracentrifugation. Cell and
virion samples were solubilized in Tris-buffered saline containing 0.5%
Triton X-100. Cell lysates were pre-cleared by adsorption with protein
G-agarose (Invitrogen). Virion and pre-cleared cell lysates were
immunoprecipitated with mouse anti-FIV p24gag (clone PAK3-2C1)
bound to protein G-agarose at 4 °C. Immunoprecipitated proteins
were washed, then resolved by SDS–PAGE, ﬁxed, and dehydrated. La-
beled proteins were detected by autoradiography on phosphorimaging
plates (Fujiﬁlm) and quantitated using QuantityOne software (Bio-
Rad). Virus release efﬁciency was calculated as the ratio of released
Gag over total Gag protein, normalized to the positive control (uninhib-
ited WT Gag).
2.4. Fusion assays
Assays to measure Env-mediated cell-cell fusion were based on
those described previously [84]. Brieﬂy, CRFK cells were transfected
in duplicate with Lipofectamine LTX PLUS reagent, and FIV Env ex-
pression vectors (pFIV-Env) containing either the WT sequence or
mutations that confer resistance to TSG-5′, to produce CRFK–Env
using the native FIV promoter. HeLa cells were seeded onto a 96-
well plate at a density of 104 cells/well and allowed to adhere over-
night at 37 °C. HeLa cultures were seeded in replicates with 500-
1,000 CRFK-Env cells, respectively, and incubated overnight at
37 °C. HeLa cells were stained with a crystal violet-Giemsa solution
in 80%methanol and destained with water. Syncytia were quantiﬁed
as giant cells containing ﬁve or more nuclei by phase contrast mi-
croscopy. Results among replicates were averaged and normalized
based on the number of CRFK–Env cells added.
2.5. Cell–cell transmission assays
CRFK cells that were chronically infected with each TSG-5′-resis-
tant FIV mutant were mixed with uninfected CRFK or T5′hi cells at a
1:20 ratio, aliquoted into 6-well plates at 0.4 million cells per well,
and incubated for 15 h at 37 °C. A semi-solid overlay consisting of
normal growth medium and 0.5% high-melting agarose was pre-
pared by boiling 1% agarose and mixing with an equal volume of
2× growth medium (2× Eagle MEM and 20% FBS supplemented
with penicillin, streptomycin, and glutamine) at room temperature,
which was then cooled to ~50 °C in a water bath. The cells were
washed with PBS, overlain with the freshly prepared semisolid me-
dium, cooled to room temperature, and incubated at 37 °C. For
each time interval, the overlay was removed with a spatula and ad-
herent cells were resuspended by trypsinization. Cell suspensions
were washed in PBS + 5% FBS, then PBS alone, resuspended in 4%
formaldehyde, incubated for 15 min, then diluted with 9 volumes
of PBS and stored at 4 °C. Fixed samples were treated in a series of
1 min incubations with 0.1 M glycine, PBS alone, 0.1% Triton X-100,
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30 min with 0.5 μgmouse anti-FIVp24 (PAK3-2C1 clone) conjugated
to Alexa Fluor 488 using Zenon labeling technology (Invitrogen).
Samples were washed with PBS and resuspended in 5% FBS/PBS for
FACS analysis. Labeled cells were detected with a BD FACSCalibur
and gated for live cells by forward and side scatter.2.6. Cell-free infectivity and reverse transcriptase assays
FIV was produced by transfection of CRFK-zeo or T5′hi cells with
Lipofectamine LTX reagent and infectious pFIV-O2R containing either
theWT or TSG-5′-resistant genomes, which establishes a chronic infec-
tion. Cell-free virus was harvested from cultured supernatants by
0.4 μm ﬁltration. 12-well culture plates were seeded with 0.3 × 106
uninfected target cells (CRFK-zeo or T5′hi) and serial dilutions of cell-
free FIV in 1 ml growth medium containing 20 μg/ml DEAE-Dextran.
Cells were incubated at 37 °C for ~24 h and virus inputs were normal-
ized by reverse transcriptase (RT) assay, using methods previously de-
scribed for HIV-1 [83]. Cultured supernatant was replaced at 1 day
post-infection with fresh growth medium. Cells were ﬁxed at 2 days
post-infection in 4% formaldehyde. FIV Gag-positive cells were stained
and counted by FACS using the same methods described above for
cell-cell transmission assays.Fig. 1. Serial passage of FIV in T5′ cells did not yield TSG-5′ resistance. A) CRFK-zeo or T5′ cells i
infected CRFK-zeo cells (FIVwt) or T5′ cells (FIV-T) at either 1 × 106 RT cpm) or 10× virus input
expressing undetectable levels of TSG-5′ are highlighted.3. Results
3.1. Enrichment for TSG-5′-positive cells enhances inhibition of FIV release
We previously described the stable and constitutive expression of
TSG-5′ in a CRFK/TSG-5′(zeo) cell line, hereafter referred to as T5′
cells, which inhibits FIV release and replication relative to control
CRFK-zeo cells [46]. In T5′ cells infected with ~100 times the minimum
infectious dose of wild-type (WT) FIV, virus replication is detectable by
RT assay after a one month delay relative to control cells. Virus
harvested under these conditions did not replicate more efﬁciently
than WT in T5′ cells in subsequent rounds of infection (Fig. 1A),
suggesting no acquisition of mutations conferring resistance. Immuno-
ﬂuorescencemicroscopy (IFM) of T5′ cells probedwith an anti-HA anti-
body revealed that approximately 1/3 of cells are TSG-5′-negative,
despite selection for a linked zeocin resistance marker (zeo) (Fig. 1B).
To eliminate cells expressing low levels of TSG-5′, which are likely per-
missive toWT FIV replication, clonal colonies of T5′ cells were screened
for TSG-5′ expression by western blot with anti-HA and normalized
with anti-tubulin (data not shown). None of the 58 viable clones
screened was entirely negative for TSG-5′ expression, however we did
observe awide range of expression levels. There was also no correlation
between high TSG-5′ expression and low cell viability, based on cell
morphology, colony size, tubulin expression, and cell doubling timesn 6-well plates were infected with cell-free preparations of FIV produced from chronically
. B) Expression of TSG-5′was detected by anti-HA IFmicroscopy in T5′ and T5′hi cells. Cells
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with western blotting results (data not shown). Twenty-four TSG-5′-
positive clones were pooled to create a TSG-5′-enriched cell line, here-
after referred to as T5′hi to distinguish it from the parental T5′ cell
line. TSG-5′ expression levels of T5′ and T5′hi cells, relative to control
cells, were quantiﬁed by ﬂow cytometry (Fig. 2A). T5′hi cells inhibited
FIV release more efﬁciently than did the parental T5′ cell line (Fig. 2B).
An increase in the proportion of cellular Gag p50 to Gag p24 in T5′hi
cells relative to T5′ cells was also consistently observed, suggesting
that the extent of p50 Gag proteolysis also correlates with TSG-5′ levels
and virus release efﬁciency.
3.2. Mutations in FIV Env confer resistance in T5′hi cells
As observed previously with the parental T5′ cells, WT FIV replica-
tion in infected T5′hi cultures was signiﬁcantly delayed, relative to rep-
lication in control cells (Fig. 3). Although TSG-5′ expression clearly
delays virus release, and TSG-5′ expression was stable throughout
each experiment, we consistently observed RT activity in the superna-
tant of infected T5′hi cells that eventually accumulated to levels equal
to those of infected control cells. Cellular DNA was obtained from cul-
tures of infected T5′hi cells that contained replicating FIV, PCR-
ampliﬁed with FIV-speciﬁc primers, and sequenced. Similar samples
were prepared from FIV-infected parental CRFK cells to control for ge-
netic variation in the absence of TSG-5′ expression. Mutations in FIVFig. 2.Enrichment for TSG-5′-expressing cells improved inhibition of virus release. A) Expression
expression is indicated by themean ﬂuorescence intensity (MFI), and the proportion of TSG-5′-
pressing CRFK cell lines relative to control CRFK zeo cells is shown as the ratio of virion-associ
phosphorimaging. p50 is the full-length FIV Gag polyprotein and p24 is FIV capsid protein. AveEnv were consistently observed in virus obtained from infected T5′hi
cells, but not in infected control cells (Fig. 4A; data not shown). One of
these mutations (K410N) is in the V3 loop of FIV Env, which has been
shown to bind heparan sulfate proteoglycans (HSPGs) and CXCR4 at
the surface of CRFK cells to promote membrane attachment and fusion
[66]. The other mutation found in Env (T762I) is at the membrane-
proximal end of the predicted heptad repeat 2 (HR2) region, which is
also involved in CXCR4-mediated membrane fusion [82,84]. Each of
these mutations was identiﬁed three times in independent isolates,
and no isolate contained both. Mutations in Gagwere also identiﬁed, in-
cluding one isolate with a G34E mutation in the nucleocapsid (NC) do-
main, and another with a conservative R36K mutation in the matrix
domain. However, each of these Gag mutations was observed in the
context of either the K410N or T762I Env mutations. FIV isolates con-
taining either Env mutation (T762I or K410N) replicated more rapidly
than WT FIV in newly infected T5′hi cells (data not shown). Several of
themutations identiﬁed through selection in T5′hi cellswere introduced
into the WT FIV proviral clone by site-directed mutagenesis, including
an FIV clone bearing only the G34Emutation in NC, which failed to rep-
licate efﬁciently in T5′hi cells (data not shown). In contrast, FIV clones
containing either the K410N or T762I Envmutation showed peak RT ac-
tivity in T5′hi cells within 3–4 weeks posttransfection, whereas WT FIV
failed to replicate efﬁciently during the course of each experiment
(Fig. 4B, lower panel). This was repeated in three independent experi-
ments in duplicate with the same result, illustrating that either Envof TSG-5′ in CRFK cell lineswas detected by anti-HA FACS analysis. Average level of TSG-5′
positive cells is relative to control CRFK-zeo cells. B) Inhibition of FIV release in TSG-5′-ex-
ated p24 to total Gag, as detected by metabolic labeling, radio-immunoprecipitation, and
rage levels of virus release are indicated.
Fig. 3. Selection for replicating FIV in T5′hi cells. CRFK-zeo or T5′hi cells in 6-well plateswere infectedwith an equal amount of FIV inparallel samples (A-F) andpassaged twice perweek. RT
activity was detected from cultured supernatants harvested prior to each passage.
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CRFK-zeo cells (not expressing TSG-5′) the WT and K410N and T762I
mutants replicated with similar kinetics (Fig. 4B, top panel).
3.3. TSG-5′-resistance mutations do not rescue virus release inhibition in
T5′hi cells and do not increase Env fusogenicity
To begin to determine themechanism of potential TSG-5′ resistance
conferred by each mutation, we ﬁrst examined whether the resistant
mutant clones were insensitive to TSG-5′-mediated restriction of virus
release. T5′hi cells were transfected with equal amounts of each mutant
proviral clone and compared with the WT in a virus release assay
(Fig. 5A). The TSG-5′-resistant FIV clones failed to release virion-
associated p24 more efﬁciently than the WT, demonstrating that these
mutations do not overcome the inhibition of virus release imposed by
TSG-5′. To determine whether mutations in FIV Env that confer resis-
tance to TSG-5′ expression might alter FIV infectivity by modulating
Env fusogenicitywith target cells, we assayed FIV Envmembrane fusion
activity in a syncytial assay that has been previously described [84].
Brieﬂy, CRFK cells transfected with a plasmid vector expressing either
WT or mutant FIV Env were cocultured with HeLa cell monolayers
overnight, then ﬁxed and stained to visualize cell membranes and
nuclei. HeLa cells express sufﬁcient CXCR4 co-receptor to fusewith plas-
ma membrane-associated FIV Env and form syncytia in a CD134-
independent manner [47,82,85]. Numbers of syncytia from multiple
replicates of each sample were averaged. Syncytia were deﬁned as
giant cells containing at least 5 nuclei. Cells expressing the FIV Env
K410N mutant consistently fused less efﬁciently with uninfected HeLa
cells than cells expressing either the WT FIV Env or the T762I Env mu-
tant (Fig. 5B). Similar results were obtained with CRFK cells chronically
infected with WT or Env-mutant FIV cocultured with HeLa cells (data
not shown). Thus, mutations in Env that confer resistance to TSG-5′
do not simply upregulate Env fusogenic activity.
3.4. CrFK T5′hi cells do not express a higher level of HSPGs or CXCR4
It has been shown that heparan sulfate proteoglycans (HSPG) and
CXCR4 serve as the primary and coreceptor for FIV infection in CRFK
cells, which lack expression of the true primary receptor CD134 that isutilized by primary isolates of FIV [47,52,53,85–88]. Since mutations
that confer resistance to TSG-5′ expressionmapped to the Envglycopro-
tein of FIV, we consideredwhether thiswas possibly a compensation for
any speciﬁc decrease in HSPG or CXCR4 expression in T5′hi cells relative
to controls. To evaluate this we measured CXCR4 and HSPG expression
in T5′hi and control CRFK cells usingmethods described previously [47].
Our results show no decrease in the expression of these cell surface
markers as a function of TSG-5′ (Fig. 5C). The low expression of CXCR4
in CRFK cells is consistent with a previous report [47]. The signiﬁcance
of the very slight increase in HSPG expression in T5′hi cells is not clear,
as this would tend to render these cells even more permissive to infec-
tion, which we also did not observe.
3.5. TSG-5′-resistant FIV mutants have greater cell-free infectivity
Considering that resistance to TSG-5′mapped to FIV Env, it is likely
that virion infectivity may have increased in order to enhance the
spread of infection. To address this possibility, we ﬁrst examined
whether TSG-5′-resistant FIV mutants have a higher speciﬁc infectivity.
Cell-free FIV was isolated from chronically infected CRFK cells and used
to infect an equal number of control CRFK or T5′hi cells over a range of
virus inputs. In parallel, RT assays were performed on each virus isolate.
The number of Gag-positive cells was then enumerated at two days
postinfection, and results were normalized to the RT activity of each
input inoculum, expressed as RT cpm per cell (Fig. 6). To compare infec-
tivity directly withWTwithout genetic selection, we only examined vi-
ruses produced in the absence of TSG-5′. Our results show that TSG-5′-
expressing cells are ~2-foldmore resistant to cell-free FIV infection than
control cells, but mutations that confer resistance to TSG-5′ did not
overcome this effect. Infections of T5′hi cells also began to saturate at
a lower virus input than control cells. Importantly, there was a signiﬁ-
cant increase in the infectivity of each TSG-5′-resistant mutant relative
to that of theWT, especially for the Env T762Imutant, whichwas entire-
ly consistent with other independent experiments.
3.6. TSG-5′-resistant FIVmutants showmore efﬁcient cell–cell transmission
Based on the TSG-5′-mediated inhibition of virus release that we
have demonstrated, we speculated that FIV-infected T5′hi cells contain
Fig. 4.Mutations in FIV Env confer resistance to TSG-5′. A) The twomutations in FIV Env thatwere detected by sequencing cDNA from infected T5′hi cells are shown to scalewith functional
domains labeled. gp95 is the surface subunit, analogous to HIV-1 gp120. gp36 is the transmembrane subunit analogous to HIV-1 gp41, which contains the two heptad repeats (HR) in-
volved in membrane fusion, the transmembrane domain (TMD), and the cytoplasmic tail (CT). B) Mutations in FIV Env that putatively conferred resistance to TSG-5′ were introduced
into the WT molecular FIV clone by site-directed mutagenesis. Mutant clones were then tested against WT FIV for replication capacity in transfected CRFK-zeo and T5′hi cells.
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cell-cell transmission would be preferentially selected. To address this
possibility, we developed an assay that indirectly quantiﬁes the rate of
FIV cell-cell transmission by restricting the diffusion of cell-free virions
with a semi-solid medium. This assay is based on methods previously
described for poxviral plaque assays [89]. With this approach, the cells
continue to grow and divide normally to form cell–cell contacts that
allow for a spreading infection. FIV-infected and uninfected CRFK cells
divide at the same rate (data not shown) and we have found that FIVinfection does not kill CRFK cells, so the proportion of FIV Gag-positive
cells increases only as a result of infectious virus replication and a
spreading infection. In T5′hi cells, the spread of WT FIV from infected
to uninfected cells remained restricted to only ~8% Gag-positive cells
within the 7 days of coculture, whereas TSG-5′-resistant Env mutants
K410N and T762I expanded 4- to 8-fold to attain 20–40% Gag-positive
cells (Fig. 7A). Even in the absence of TSG-5′ expression, TSG-5′-resis-
tant mutants consistently spread more rapidly under semi-solid over-
lays to infect ~35–45% of cells within 5 days, whereas the spread of
Fig. 5. TSG-5′ resistance mutations do not rescue virus release or enhance membrane fusion. A) T5′hi cells were transfected with mutant FIV clones and compared with WT FIV for virus
release efﬁciency, as detected by metabolic labeling, radio-immunoprecipitation, and phosphorimaging. B) Results from coculture of FIV Env-expressing CRFK cells and HeLa cells, ﬁxed
and stainedwith crystal violet, are shown as the average number of syncytia counted per well in a 96-well plate. C) Flow cytometry of CXCR4 and HSPG expression in CRFK and T5′hi cells.
Primary antibodies were labeled with Alexa Fluor 488-conjugated anti mouse IgG (Invitrogen). CXCR4 was detected with mouse anti-human CXCR4 (clone 44717) obtained through the
NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH. HSPGs were detected with mouse anti-heparan sulfate clone F58-10E4 (Seikagaku America), as described previously [47].
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(Fig. 7B). This contrasts with the results shown in Fig. 4B, perhaps be-
cause the spread of infection is limited by agarose and the amount of
cell-free virus is no longer in excess, similar to conditions where virus
release is inhibited. The detection of Gag-positive cells as a measure of
a spreading infectionwith thismethod is alsomore accurate and precise
than detecting RT activity released into the supernatant. These results
suggest that TSG-5′-resistant mutants are more efﬁcient in cell–cell
transmission, and that this property is associated with Env function.
4. Discussion
We have demonstrated that FIV can develop partial resistance to a
constitutive inhibition of virus release, which in this study was mediat-
ed by expression of a dominant interfering N-terminal fragment of cel-
lular TSG101 (TSG-5′). Our results suggest that enhancements of virion
infectivity and possibly cell-to-cell transmission by mutations in either
the V3 loop or the HR2 domain of the Env glycoprotein provide mecha-
nisms for this resistance. We had initially speculated the acquisition ofTSG-5′-resistance by mutation of FIV Env (K410N) in the V3 loop
would possibly affect virion binding afﬁnity to CXCR4 and HSPGs, either
positively or negatively, based on the reported correlations between
overall net charge in this region and coreceptor afﬁnity [65,90]. It has
been shown that the net charge in the V3 loop differs between lab-
adapted isolates grown in cell culture and primary isolates obtained
from infected cats, which is actively maintained by selective pressures
in both environments [68–70,91]. Since our study focused on FIV repli-
cation mediated by CD134-independent entry, the selection for resis-
tance may have favored mutations in the HSPG or CXCR4-binding
regions of FIV Env that aremore highly utilized by the 34TF10molecular
clone. To avoid some of these limitations, we had engineered the FIV
molecular clone used in this study to encode a full-length ORF2/ORF-
A, which expands its host range to include CD134-positive feline T cell
lines and potentially PBMCs [76]. However, our efforts to stably express
high levels of TSG-5′ in the MCH5-4 feline T cell line have not yet been
successful.We did not observe any signiﬁcant change in HSPG or CXCR4
levels in CRFK cells expressing TSG-5′ relative to parental cells that
would explain the advantage of acquiring a mutation in this domain,
Fig. 6. TSG-5′ resistance mutations enhance FIV speciﬁc infectivity. TSG-5′-resistant FIV
mutant clones and WT FIV were harvested from the supernatant of chronically infected
CRFK-zeo cells and added to uninfected CRFK-zeo or T5′hi cells in 2-fold serial dilutions
and mixed with DEAE-Dextran. At two days postinfection, cells were resuspended and
ﬁxed in 4% formaldehyde, then stained with mouse anti-p24 conjugated to Alexa Fluor
488 and quantiﬁed by ﬂow cytometry.
Fig. 7. TSG-5′ resistance mutations enhance cell-cell FIV transmission. CRFK-zeo cells
chronically infected with either WT FIV or one of the TSG-5′-resistant mutants were
counted and mixed with uninfected CRFK-zeo or T5′hi cells in suspension at a ﬁnal ratio
of 1:20 (5% Gag-positive cells). Cell mixtures were aliquoted in cell culture plates and in-
cubated overnight. Adherent cells were washed to remove any released cell-free virions
and covered with melted growth medium containing 0.5% high-melting agarose, then in-
cubated at 37 °C. For each time interval, overlays were removed and the cell monolayer
was resuspended,washed, andﬁxed. FIVp24was later detected in allﬁxed samples by im-
munoﬂuorescence and ﬂow cytometry. Cells from the initial coculturewere also ﬁxed and
analyzed to verify the baseline ratio of infected cells.
1150 B.G. Luttge et al. / Biochimica et Biophysica Acta 1838 (2014) 1143–1152however any speciﬁc changes in afﬁnity remain to be evaluated. During
the course of this study the CXCR4 and HSPG-binding sites of FIV Env
were more clearly identiﬁed by Hu et al., which includes the lysine res-
idue at position 410 of the same molecular clone of FIV Petaluma
(34TF10) used in our study [65,66]. We had also speculated that the ac-
quisition of TSG-5′ resistance bymutation of the HR2 domain of FIV Env
(T762I) would possibly affect Env-mediated membrane fusion, since
the coiled-coil interaction between HR2 and HR1 is critical for fusion
[92]. Notably, the HR2 domain of HIV-1 Env is the source of the antiviral
peptide enfuvirtide (T20, fuzeon), which functions as a competitive in-
hibitor of HR1 binding [93,94].Wewere surprised to ﬁnd that fusion ac-
tivity of the T762I mutant is paradoxically diminished, given that our
HR2 mutant is more infectious and spreads more efﬁciently from cell
to cell. In parallel studies, we have also observed mutations in HIV-1
Env that are selected in the presence of Alix binding site mutants,which again appear to enhance cell-to-cell transmission (unpublished
results).
Consistent with our previous report [46], the inhibition of virus re-
lease through stable expression of TSG-5′ had no deleterious effect on
cell viability. We have also developed a Jurkat cell line stably expressing
a signiﬁcant level of TSG-5′, which has no effect on cell viability and
moderately inhibits the replication of the HIV-1 clone NL4-3
(unpublished results). Given that our FIV molecular clone did not ac-
quire any mutations that fully restored virus replication kinetics in the
presence of this late domain inhibitor, and that mutations that did pro-
vide resistance did not restore virus release efﬁciency, this study pro-
vides proof of principle that interference of late domain function is a
difﬁcult block for the virus to circumvent through any single nucleotide
change. Serial passages of resistant FIV isolates also did not lead to any
secondary mutations that would possibly have improved viral ﬁtness
(data not shown). This stresses the importance of the TSG101-Gag in-
teraction to efﬁcient virus release, and that there is little redundancy
1151B.G. Luttge et al. / Biochimica et Biophysica Acta 1838 (2014) 1143–1152in this pathway. This is encouraging if development of small molecule
inhibitors of this interface is to be pursued further as an antiviral thera-
py. Furthermore, our results suggest that interference of late domain
function should be combinedwith inhibitors of cell-to-cell transmission
to be even more effective.
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